Oxford Nanopore Technologies plc
25 August 2026
25 August 2026
Oxford Nanopore Technologies plc
("Oxford Nanopore" or the "Company")
Appointment of Chief Development and Product Officer
Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore-based molecular sensing], today announces the appointment of David Miller as Chief Development and Product Officer (CDPO), joining on 1st September. The Company also confirms that Conor McKechnie will join as Chief Marketing and Communications Officer (CMCO) on 1st October, as previously announced.
Together, these appointments strengthen the Oxford Nanopore's leadership team, bringing greater alignment between product development, market positioning and commercial execution.
As CDPO, David will lead Product Management, Development and Applications, strengthening the connection between the Company's strategy, development priorities and product portfolio. David joins Oxford Nanopore from Pacific Biosciences, where he served as Head of Research & Development and Vice President, Global Marketing. Prior to that, he held senior product leadership roles at Illumina, including responsibility for major platform launches.
As CMCO, Conor will lead Oxford Nanopore's global Marketing and Corporate Affairs functions, with responsibility for strengthening market positioning, customer engagement and the Company's corporate and technology narratives. Conor joins from Cytiva, where he has served as Group Vice President, Marketing. He previously held senior marketing, communications and public affairs roles at GE Healthcare.
Francis Van Parys, Chief Executive Officer of Oxford Nanopore, commented: "As we scale Oxford Nanopore, we are strengthening our leadership team to deepen our focus on customers and accelerate the translation of our differentiated technology into high-performing products, applications and successful customer adoption. David and Conor bring deep experience across product development, commercialisation, customer and market adoption, and will play important roles as we increase our focus on disciplined execution and sustainable growth."
David Miller said: "Oxford Nanopore has built a truly differentiated technology platform with enormous potential. I'm excited by the opportunity to bring together product development and applications to turn that innovation into high-performing products and solutions that solve important problems for customers."
Conor McKechnie said: "Oxford Nanopore has an exceptional technology platform and a significant opportunity across Research, Clinical and BioPharma. I'm looking forward to working with the team to strengthen how we engage with customers and stakeholders, build understanding of the value Oxford Nanopore can deliver, and support the Company's next phase of growth."
Both David and Conor will join Oxford Nanopore's Executive team.
-ENDS-
For further information, please contact:Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Teneo (communications adviser to the Group)
Tom Murray, Lisa Jarrett-Kerr
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.